Ardelyx, Inc.

NASDAQ:ARDX

Biotechnology

Healthcare
$3.12 -1.03%

-$0.06 today

Market cap
$784.28M
Beta
0.58
P/E (TTM)
-24.5
EPS (TTM)
-$0.24
52W Low $3.49High $8.40

Volume 4.75M

Average 3.58M

ARDX Effect of Forex Changes

Change in reported cash caused by exchange-rate movements on foreign-currency balances.

Ardelyx, Inc.NASDAQ: ARDX

Effect of Forex Changes · Q1 FY2026 · quarter ended Mar 2026

Effect of forex changes outflow grows to $0

Q1 FY2026 effect of forex changes was $0, compared with $0 a year earlier. Trailing-twelve-month effect of forex changes was $0.

Context

  • Effect of forex changes amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Effect of forex changes increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly effect of forex changes holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Effect of Forex Changes past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Effect of Forex Changes history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Effect of Forex Changes vs competitors

How ARDX compares with its peers on the latest reported figures

  • ARDX's LTM Mar 2026 effect of forex changes of $0 is the 3rd largest of the 5 companies compared; the peer median is $0.
  • Effect of forex changes amounts to 0.0% of revenue for ARDX, versus a peer median of 0.0%.
ARDX Competitors Peer median
Effect of Forex Changes for ARDX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$15.21K ———
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$5K -61.5%—0.0%
ARDXArdelyx, Inc.LTM Mar 2026$0 ——0.0%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$0 ——0.0%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding ARDX) $0-61.5%—0.0%

Competitors are the stored peer set for ARDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(158.17M)(67.21M)(66.07M)(39.14M)(61.6M)
Depreciation & Amortization1.44M1.14M1.29M2.06M3.06M
Deferred Income Tax(190K)0000
Stock-Based Compensation12.04M10.75M13.53M37.38M48.96M
Change in Working Capital(11.92M)(19.58M)(43.39M)(49.17M)(31.35M)
Accounts Receivables(502K)(7.23M)(14.3M)(35.67M)(14.14M)
Inventory(10.37M)(28.35M)(21.14M)(41.7M)(31.92M)
Accounts Payables(1.35M)6.58M279K4.86M3.24M
Other Working Capital300K9.42M(8.23M)23.34M11.48M
Other Non-Cash Items4.25M4.84M4.91M4.05M(1.55M)
Operating Cash Flow(152.55M)(70.04M)(89.72M)(44.81M)(42.48M)
Capital Expenditures(1.87M)(55K)(344K)(1.01M)(1.49M)
Acquisitions (Net)(52.82M)0000
Purchases of Investments(72.74M)(50.33M)(215.23M)(195.16M)(218.92M)
Sales of Investments125.55M67M84.32M177.85M211.46M
Other Investing Activities52.82M1.8M000
Investing Cash Flow50.95M18.42M(131.25M)(18.32M)(8.96M)
Debt Repayment(19.44M)(6.07M)22.39M99.45M48.67M
Common Stock Issued101.15M71.63M119.24M8.14M5.84M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.3M9.78M4.67M(1M)0
Financing Cash Flow83M75.34M146.3M106.59M54.51M
Effect of Forex Changes00000
Net Change in Cash(18.6M)23.71M(74.67M)43.46M3.07M
Free Cash Flow(154.42M)(70.1M)(90.06M)(45.82M)(43.98M)

Ardelyx, Inc.

NASDAQ:ARDX

Intrinsic Alpha fair value

Locked

Current Price

$3.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.